Combined with Genetron’s universal tumor database, the solid tumor 825 genes testing covers an updated version of the WHO, NCCN, ESMO and other authoritative guidelines and expert consensus recommended test genes. Based on the high-throughput, highly sensitive NGS platform and 'hybrid capture' technology, solid tumor 825 genes testing can provide multi-dimensional immunotherapy related biomarker detection (TMB, MSI, PD-L1, immune efficacy related gene variation), so as to guide the individualized diagnosis and treatment of tumor patients more accurately, It also provides more comprehensive reference information for researchers

1. Focus on 238 tumor drugs, covering 12 classic tumor signaling pathways, 45 chemotherapy drug related sites, 90 immunotherapy related genes, 149 tumor genetic susceptibility genes
2. Comprehensive and real-time dynamic monitoring of recurrent metastasis and the mechanism of molecular change in drug-resistant patients, to achieve the full course of cancer monitoring and management
3. Multi-dimensional immunotherapy assessment

Tumor patients seeking more opportunities for targeted drugs or immunotherapy

The urothelial carcinoma risk gene testing is a non-invasive test product based on urine liquid biopsy technology which can assist in differentiating benign and malignant upper urinary tract lesions. It can also offer early assessment of the risk of urothelial tumors in patients with symptoms such as hematuria, and reduce the pain of invasive examinations (e.g.  cystoscopy) in low-risk patients

1. Unique urine biopsy products:
Effective auxiliary diagnosis, early detection of tumor to avoid tumor cell metastasis; Avoid frequent traumatic examinations and improve the compliance of patients with re-examinations
2. Accurate results:
Sensitivity＞95%, Negative prediction rate～99%

1. Hematuria patients who need auxiliary diagnosis for urothelial carcinoma
2. Suspected upper urinary tract tumor patients in need of auxiliary diagnosis
3. Intermediate and high-risk bladder cancer patients who require frequent review